Published in J Immunol on November 01, 2002
Adoptive T cell therapy for cancer in the clinic. J Clin Invest (2007) 3.45
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res (2010) 1.92
STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells. Blood (2008) 1.06
Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells. J Transl Med (2004) 1.02
Cellular mechanisms of multiple myeloma bone disease. Clin Dev Immunol (2013) 0.96
From "Hellstrom Paradox" to anti-adenosinergic cancer immunotherapy. Purinergic Signal (2007) 0.90
Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol (2012) 0.88
Rebuilding immunity in cancer patients. Blood Cells Mol Dis (2007) 0.88
Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? Purinergic Signal (2012) 0.88
Microenvironment of tumor-draining lymph nodes: opportunities for liposome-based targeted therapy. Int J Mol Sci (2014) 0.84
Changes of Th17/Treg cell and related cytokines in pancreatic cancer patients. Int J Clin Exp Pathol (2015) 0.83
Antitumor activity of T cells generated from lymph nodes draining the SEA-expressing murine B16 melanoma and secondarily activated with dendritic cells. Int J Biol Sci (2009) 0.80
Tumor-primed, in vitro-activated CD4+ effector T cells establish long-term memory without exogenous cytokine support or ongoing antigen exposure. J Immunol (2010) 0.79
Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett (2015) 0.78
Requirement of Innate Immunity in Tumor-Bearing Mice Cured by Adoptive Immunotherapy Using Tumor-Draining Lymph Nodes. J Immunol Res (2015) 0.75
Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med (2012) 6.73
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res (2007) 2.25
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res (2010) 1.92
Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol (2008) 1.69
Intracellular hyaluronan: a new frontier for inflammation? Biochim Biophys Acta (2004) 1.64
Circulating cells with osteogenic potential are physiologically mobilized into the fracture healing site in the parabiotic mice model. J Orthop Res (2008) 1.52
Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol (2003) 1.50
A Plasmodium gene family encoding Maurer's cleft membrane proteins: structural properties and expression profiling. Genome Res (2004) 1.49
Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother (2002) 1.47
Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc Natl Acad Sci U S A (2011) 1.46
Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer (2011) 1.39
Cutting edge: innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells. J Immunol (2004) 1.38
Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol (2003) 1.34
HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant (2004) 1.27
Autophagy-dependent senescence in response to DNA damage and chronic apoptotic stress. Autophagy (2012) 1.17
Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells. Cancer Res (2005) 1.16
Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. Cancer Res (2008) 1.16
IL-12 is required for anti-OX40-mediated CD4 T cell survival. J Immunol (2008) 1.14
Reengineering dendritic cell-based anti-cancer vaccines. Immunol Rev (2008) 1.09
STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells. Blood (2008) 1.06
Proteolytic cleavage of cyclin E leads to inactivation of associated kinase activity and amplification of apoptosis in hematopoietic cells. Mol Cell Biol (2002) 1.05
Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells. J Transl Med (2004) 1.02
Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res (2014) 1.01
CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J Immunol (2007) 1.00
Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines. J Neurosurg (2005) 0.96
Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol (2002) 0.95
Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII). Laryngoscope (2006) 0.94
Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J Immunother (2004) 0.94
Oxidized LDL/CD36 interaction induces loss of cell polarity and inhibits macrophage locomotion. Mol Biol Cell (2012) 0.94
Adenovirus type 5 vectors induce dendritic cell differentiation in human CD14(+) monocytes cultured under serum-free conditions. Blood (2002) 0.92
Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy. J Immunol (2004) 0.92
Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells. Clin Immunol (2008) 0.91
Viewing hyaluronan: imaging contributes to imagining new roles for this amazing matrix polymer. J Histochem Cytochem (2011) 0.91
Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics. Cancer J (2013) 0.90
Therapeutic efficacy of adoptive immunotherapy is predicated on in vivo antigen-specific proliferation of donor T cells. Clin Immunol (2003) 0.90
Depressed peroxisome proliferator-activated receptor gamma (PPargamma) is indicative of severe pulmonary sarcoidosis: possible involvement of interferon gamma (IFN-gamma). Sarcoidosis Vasc Diffuse Lung Dis (2006) 0.89
Cell viability mapping within long-term heart valve organ cultures. J Heart Valve Dis (2004) 0.88
Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy. Int J Cancer (2013) 0.87
Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol (2012) 0.87
Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion. J Immunol (2002) 0.87
Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell Immunol (2002) 0.86
Catecholestrogens induce oxidative stress and malignant transformation in human endometrial glandular cells: protective effect of catechol-O-methyltransferase. Int J Cancer (2008) 0.85
Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination. Cell Immunol (2007) 0.85
Autophagic flux determines cell death and survival in response to Apo2L/TRAIL (dulanermin). Mol Cancer (2014) 0.84
Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist. Chembiochem (2014) 0.84
Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell Immunol (2003) 0.84
Effect of multiple activation stimuli on the generation of Th1-polarizing dendritic cells. Hum Immunol (2010) 0.84
Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy. Crit Rev Immunol (2007) 0.83
Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines. Head Neck (2010) 0.81
Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes. Crit Rev Immunol (2007) 0.80
Postallograft donor and recipient dendritic cell trafficking in the rat larynx. Laryngoscope (2007) 0.80
Immune response to cancer and its regulation in regional lymph nodes. J Surg Oncol (2011) 0.80
Tumor-dendritic cell fusion as a basis for cancer immunotherapy. Otolaryngol Head Neck Surg (2005) 0.80
Rhop-3 protein conservation among Plasmodium species and induced protection against lethal P. yoelii and P. berghei challenge. Parasitol Res (2006) 0.80
Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy. Cancer Treat Res (2007) 0.79
Tumor-primed, in vitro-activated CD4+ effector T cells establish long-term memory without exogenous cytokine support or ongoing antigen exposure. J Immunol (2010) 0.79
Extracellular ATP and Toll-like receptor 2 agonists trigger in human monocytes an activation program that favors T helper 17. PLoS One (2013) 0.78
Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide. Chem Commun (Camb) (2015) 0.78
Considerations on clinical use of T cell immunotherapy for cancer. Arch Immunol Ther Exp (Warsz) (2003) 0.78
Plasmodium yoelii: novel rhoptry proteins identified within the body of merozoite rhoptries in rodent Plasmodium malaria. Exp Parasitol (2008) 0.77
Downregulation of hematopoietic MUC1 during experimental colitis increases tumor-promoting myeloid-derived suppressor cells. Clin Cancer Res (2013) 0.77
Collagen remodeling and suburethral inflammation might account for preserved anti-incontinence effects of cut polypropylene sling in rat model. Urology (2008) 0.77
Actin cytoskeleton remodeling by the alternatively spliced isoform of PDLIM4/RIL protein. J Biol Chem (2011) 0.76
Immunotherapy using allogeneic squamous cell tumor-dendritic cell fusion hybrids. Head Neck (2010) 0.75
T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumors. Breast Cancer Res Treat (2011) 0.75
Adoptive immunotherapy. Methods Mol Med (2003) 0.75
Immunotherapy of established murine squamous cell carcinoma using fused dendritic-tumor cell hybrids. Arch Otolaryngol Head Neck Surg (2008) 0.75
Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide. Chembiochem (2017) 0.75
Quantitative analysis of OX62-positive dendritic cell distribution in the rat laryngeal complex. Ann Otol Rhinol Laryngol (2007) 0.75
[Immunotherapeutic reactivity of dendritic cells loaded with a variety of antigen preparations]. Gan To Kagaku Ryoho (2004) 0.75
RAD inhibition of sarcoma growth: implications for laryngeal transplantation. Am J Otolaryngol (2007) 0.75